Imutex is a pioneering brand focused on developing vaccines to combat the threat of influenza and mosquito-borne diseases. As a joint venture between PepTcell and hVIVO, Imutex is at the forefront of vaccine development. Their flagship product, FLU-v, is a Broad-Spectrum 'Universal' Influenza Vaccine designed to provide protection against multiple flu strains.

Leveraging technology licensed from PepTcell, Imutex is harnessing the power of cytotoxic T cells to clear viruses and stimulate a strong immune response. In addition to their influenza vaccine, Imutex has also developed AGS-v, a groundbreaking vaccine against mosquito-borne diseases. By preventing human infection and controlling the mosquito population, AGS-v offers a novel dual action mechanism for disease prevention.

Led by an experienced team of experts, Imutex is dedicated to improving global health outcomes. If you want to learn more about their groundbreaking vaccines and groundbreaking advancements, get in touch with Imutex today